US › Healthcare

Insulet Corporation (PODD)

US · Healthcare · Medical Devices

$166.82-1.70%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$761.7M
Revenue YoY
+33.9%
Net profit
$91.1M
Profit YoY
+157.3%
EPS
$1.42
EPS estimate
$1.19
Net margin
12.0%

EPS came in at 1.42 against a street estimate of 1.19 — a beat of 19.3%.

Key statistics

Market cap
$11.75B
P/E
39.6
Forward P/E
26.6
P/B
8.79
Book value
$18.81
EPS (TTM)
$4.28
52-week high
$354.88
52-week low
$138.79
50-day MA
$155.32
200-day MA
$232.15
Beta
1.09

Analyst view

Analysts rate Insulet Corporation a strong buy (21 buy, 3 hold, 0 sell out of 24) with an average price target of $235.54.

Shareholding

Insiders
0.33%
Institutions
105.30%

Largest institutional holders

FundStake
Vanguard Group Inc12.56%
BlackRock Inc9.21%
Vanguard Capital Management, LLC6.61%
FMR Inc5.74%
Vanguard Portfolio Management, LLC4.98%
State Street Corp4.39%
Baillie Gifford & Co Limited.2.93%
Geode Capital Management, LLC2.92%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Insulet Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.